



Sensorion announces positive results from a preclinical trial on recovering hearing following acoustic trauma

This data enables the launch of a clinical trial in this new indication to be envisaged

Abstract submitted for Neuroscience 2015

Montpellier, June 4, 2015 (FR0012596468 – ALSEN) – Sensorion, a biotech specialising in the treatment of inner ear diseases, today announces that positive results have been obtained from a proof-of-concept in vivo preclinical trial on a new drug candidate aimed at the curative treatment of severe hearing loss.

No effective drug is currently available to treat disabling sensorineural hearing loss induced by acoustic trauma, which affects some 11 million patients worldwide¹.

Sensorion selected, through its screening platform, a small-molecule drug candidate that can be taken orally and is capable of reducing the impact of injury process associated with acoustic trauma. These processes affect the inner ear's neurosensory tissue and lead to hearing loss.

Within the framework of this proof-of-concept in vivo preclinical trial, animals in which acute bilateral sensorineural hearing loss was induced by major sustained acoustic trauma were randomly treated over fourteen consecutive days with either the drug candidate or a placebo. Those treated via the systemic administration of this small molecule each day experienced a 60% improvement in their sensorineural hearing ability on average, compared with the placebo group, or an improvement in their hearing of around 40 dB.

Sensorion has submitted an abstract to present these results at the Society for Neuroscience's 45th annual meeting (Neuroscience 2015), which will take place from October 17 to 21, 2015 in Chicago.

Pierre Attali, Sensorion's Chief Medical Officer, says: *"This preclinical trial has proven the efficacy of our treatment in animals within the context of a trauma replicating the clinical situation observed in humans, by leading to a substantial improvement in, or even the full recovery of, the subject's hearing. The results obtained by this trial are very promising, as they enable the carrying out of clinical trials on humans to be envisaged. Furthermore, in accordance with our strategy, this treatment can be taken orally rather than via an invasive transtympanic injection, which makes us very different from the few existing inner-ear pioneers."*

Laurent Nguyen, CEO of Sensorion, adds: *"This new data, obtained only a few weeks after our IPO, proves our screening platform's ability to rapidly identify new indications in the inner ear segment for new or de-risked-in-human molecules. This new indication – severe hearing loss – will enable us to expand our access to the inner ear disorders market."*

•••

About Sensorion

Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech that specialises in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. Backed by its pharmaceutical R&D experience and a comprehensive technology platform, Sensorion is developing three drug candidate programmes for treating the symptoms of vertigo or tinnitus, for preventing complications associated with progressive lesions in the inner ear and for preventing the toxicity of

¹ Source: Alcimed, Sensorion

chemotherapy in the inner ear. Based in Montpellier, southern France, within the university and hospital hub, Sensorion has a portfolio of 7 patent families, employs 15 staff and receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

For more information: www.sensorion-pharma.com

Contacts

Sensorion

Laurent Nguyen

CEO

contact@sensorion-pharma.com

Tel: +33 (0)4 67 20 77 30

Name: **SENSORION**

ISIN code: **FR0012596468**

Ticker: **ALSEN**

NewCap

Dusan Oresansky / Emmanuel Huynh

Investor Relations & Strategic communications

sensorion@newcap.fr

Tel: +33 (0)1 44 71 94 92

ALSEN
LISTED
ALTERNEXT



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 15-114 on March 27, 2015 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.